Drug Profile


Alternative Names: GENHP-01; GNN001

Latest Information Update: 30 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeNeuro
  • Class Antihyperglycaemics; Immunotherapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Toll-like receptor 4 antagonists; Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic inflammatory demyelinating polyradiculoneuropathy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Type 1 diabetes mellitus
  • Phase I Chronic inflammatory demyelinating polyradiculoneuropathy

Most Recent Events

  • 10 Oct 2018 Interim efficacy, pharmacokinetics and adverse events data from a phase IIb CHANGE-MS trial in multiple sclerosis presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2018)
  • 18 Sep 2018 GeNeuro Regains Worldwide Rights excluding US and Japan to GNbAC1 in Multiple Sclerosis from Servier
  • 18 Sep 2018 GNbAC1 is available for licensing as of 18 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top